High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

被引：13

作者：

Huang, Wenrong ^{[1
]}

Li, Jian ^{[2
]}

Li, Honghua ^{[1
]}

Kang, Wenying ^{[2
]}

Bo, Jian ^{[1
]}

Zhao, Yu ^{[1
]}

Gao, Chunji ^{[1
]}

Zhou, Daobin ^{[2
]}

Yu, Li ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China

[2] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 12期

关键词：

INTERGROUPE FRANCOPHONE; DEXAMETHASONE; VINCRISTINE; PREDNISONE; PHASE-2; TRIAL;

D O I：

10.3109/10428194.2012.685735

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2507 / 2510

页数：4

共 15 条

[11] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].

Richardson, PG ;

Sonneveld, P ;

Schuster, MW ;

Irwin, D ;

Stadtmauer, EA ;

Facon, T ;

Harousseau, JL ;

Ben-Yehuda, D ;

Lonial, S ;

Goldschmidt, H ;

Reece, D ;

San-Miguel, JF ;

Bladé, J ;

Boccadoro, M ;

Cavenagh, J ;

Dalton, WS ;

Boral, AL ;

Esseltine, DL ;

Porter, JB ;

Schenkein, D ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498

[12] Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) [J].

Roussel, Murielle ;

Moreau, Philippe ;

Huynh, Anne ;

Mary, Jean-Yves ;

Danho, Clotaire ;

Caillot, Denis ;

Hulin, Cyrille ;

Fruchart, Christophe ;

Marit, Gerald ;

Pegourie, Brigitte ;

Lenain, Pascal ;

Araujo, Carla ;

Kolb, Brigitte ;

Randriamalala, Edouard ;

Royer, Bruno ;

Stoppa, Anne-Marie ;

Dib, Mammoun ;

Dorvaux, Veronique ;

Garderet, Laurent ;

Mathiot, Claire ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Attal, Michel .

BLOOD, 2010, 115 (01) :32-37

[13] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J].

San Miguel, Jesus F. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Dimopoulos, Meletios A. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Petrucci, Maria T. ;

Palumbo, Antonio ;

Samoilova, Olga S. ;

Dmoszynska, Anna ;

Abdulkadyrov, Kudrat M. ;

Schots, Rik ;

Jiang, Bin ;

Mateos, Maria-Victoria ;

Anderson, Kenneth C. ;

Esseltine, Dixie L. ;

Liu, Kevin ;

Cakana, Andrew ;

van de Velde, Helgi ;

Richardson, Paul G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09) :906-917

[14] A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid [J].

Sharma, Manish ;

Khan, Hassan ;

Thall, Peter F. ;

Orlowski, Robert Z. ;

Bassett, Roland L., Jr. ;

Shah, Nina ;

Bashir, Qaiser ;

Parmar, Simrit ;

Wang, Michael ;

Shah, Jatin J. ;

Hosing, Chitra M. ;

Popat, Uday R. ;

Giralt, Sergio A. ;

Champlin, Richard E. ;

Qazilbash, Muzaffar H. .

CANCER, 2012, 118 (09) :2507-2515

[15] Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma [J].

Thompson, P. A. ;

Prince, H. M. ;

Seymour, J. F. ;

Ritchie, D. ;

Stokes, K. ;

Burbury, K. ;

Wolf, M. ;

Peinert, S. ;

Joyce, T. ;

Harrison, S. J. .

BONE MARROW TRANSPLANTATION, 2011, 46 (05) :764-765

← 1 2 →